Literature DB >> 19772676

Carcinosarcoma of the ovary a review.

Leigh A Cantrell1, Linda Van Le.   

Abstract

Carcinosarcoma of the ovary, also referred to as mixed mullerian tumor of the ovary, is a rare and aggressive tumor. This tumor type is unique in that it contains malignant epithelial and stromal elements. The average survival for a woman diagnosed with carcinosarcoma of the ovary is less than 2 years. Due to the rarity of this tumor, the optimal treatment for carcinosarcoma of the ovary has not been determined. We review the pathology, risk factors, and current treatment recommendations for carcinosarcoma of the ovary.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19772676     DOI： 10.1097/OGX.0b013e3181b8aff3

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN： 0029-7828            Impact factor:   2.347


  14 in total

1.  T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Authors:  Roberta Nicoletti; Salvatore Lopez; Stefania Bellone; Emiliano Cocco; Carlton L Schwab; Jonathan D Black; Floriana Centritto; Liancheng Zhu; Elena Bonazzoli; Natalia Buza; Pei Hui; Delia Mezzanzanica; Silvana Canevari; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2014-11-15       Impact factor: 5.150

Review 2.  Biphasic malignant tumours of the abdominal cavity.

Authors:  L Max Almond; Adrian T Warfield; Anant Desai; David Gourevitch; Samuel J Ford
Journal:  Int J Clin Oncol       Date:  2017-06-27       Impact factor: 3.402

3.  HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas.

Authors:  Federica Guzzo; Stefania Bellone; Natalia Buza; Pei Hui; Luisa Carrara; Joyce Varughese; Emiliano Cocco; Marta Betti; Paola Todeschini; Sara Gasparrini; Peter E Schwartz; Thomas J Rutherford; Roberto Angioli; Sergio Pecorelli; Alessandro D Santin
Journal:  Int J Gynecol Pathol       Date:  2012-05       Impact factor: 2.762

4.  Synchronous occurrence of primary malignant mixed müllerian tumor in ovary and uterus.

Authors:  Tae Yeon Lee; Chulmin Lee; Won Jun Choi; Ji Young Lee; Heung Yeol Kim
Journal:  Obstet Gynecol Sci       Date:  2013-07-15

5.  Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor.

Authors:  S Vernadakis; D Moris; C Delimpalta; J Bokos; G Zavos
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

Review 6.  Imaging Features of Uncommon Gynecologic Cancers.

Authors:  Maura Miccò; Evis Sala; Yulia Lakhman; Hedvig Hricak; Hebert Alberto Vargas
Journal:  AJR Am J Roentgenol       Date:  2015-12       Impact factor: 3.959

7.  Experience of the pancreas duodenectomy for so-called carcinosarcoma of the common bile duct:a case report and review of literature.

Authors:  Suguru Sasamoto; Takeshi Aoki; Yoshihiko Tashiro; Kazuhiro Matsuda; Tomotake Koizumi; Tomokazu Kusano; Yusuke Wada; Hideki Shibata; Kodai Tomioka; Takeshi Yamashita; Hiromi Date; Tomotake Ariyoshi; Satoru Goto; Kimiyasu Yamazaki; Akira Fujimori; Makoto Watanabe; Yuta Enami; Koji Otsuka; Tomoko Norose; Nobuyuki Ohike; Toshiko Yamochi; Masafumi Takimoto; Masahiko Murakami
Journal:  Int Cancer Conf J       Date:  2021-01-03

8.  Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody.

Authors:  Rhoda Raji; Federica Guzzo; Luisa Carrara; Joyce Varughese; Emiliano Cocco; Stefania Bellone; Marta Betti; Paola Todeschini; Sara Gasparrini; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter Schwartz; Thomas J Rutherford; Natalia Buza; Sergio Pecorelli; Alessandro D Santin
Journal:  J Exp Clin Cancer Res       Date:  2011-11-10

9.  Presence of both Mesenchymal and Carcinomatous Features in an In-vitro Model of Ovarian Carcinosarcoma Derived from Patients' Ascitic Fluid.

Authors:  Ahmad Shariftabrizi; Ilenia Pellicciotta; Amer Abdullah; Charis Anne Venditti; Robert Samuelson; Shohreh Shahabi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-01-01

10.  Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro.

Authors:  Francesca Ferrari; Stefania Bellone; Jonathan Black; Carlton L Schwab; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Federica Predolini; Gulden Menderes; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  J Exp Clin Cancer Res       Date:  2015-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.